• Rapamycin-Induced Autophagy Alleviates Lipotoxicity in Salmo

  2026-06-26

  The reference study establishes that rapamycin-induced autophagy enhances lipid breakdown and mitigates lipotoxicity in Atlantic salmon SHK-1 cells. These findings expand our understanding of autophagy’s role in lipid regulation within economically significant aquaculture species, with practical implications for improving fish health and managing diet-induced metabolic stress.

• FXR-KLF11 Pathway: CDCA Mitigates Contrast-Induced Kidney In

  2026-06-26

  A recent study uncovers that Chenodeoxycholic Acid (CDCA) confers significant protection against contrast-induced acute kidney injury (CI-AKI) by activating the FXR-KLF11 axis and suppressing the JAK2/STAT3 pathway. This mechanistic insight advances both our understanding of CI-AKI pathogenesis and the translational potential of FXR agonists in renal protection.

• Cell Cycle Assay Kit: Precision Analysis of G0/G1, S, and G2

  2026-06-25

  Unlock high-fidelity cell cycle progression analysis with the Cell Cycle Assay Kit (Catalog No. K2263), optimized for robust detection of cell cycle phases and apoptosis via flow cytometry. This article guides you through advanced protocols, real-world troubleshooting, and strategic use in translational cancer research.

• Lanabecestat (AZD3293): Precision BACE1 Inhibition for Alzhe

  2026-06-25

  Lanabecestat (AZD3293) delivers reproducible, blood-brain barrier-penetrant BACE1 inhibition, enabling nuanced amyloid-beta modulation without compromising synaptic function. This guide translates recent experimental advances into actionable protocols, troubleshooting tips, and comparative insights for Alzheimer’s disease research teams seeking reliable, translational models.

• Biotin-XX Tyramide: Advancing Selective Cell Surface Proteom

  2026-06-24

  A thought-leadership article for translational researchers, exploring the mechanistic and strategic advantages of Biotin-XX Tyramide Reagent in cell surface protein profiling. This piece synthesizes recent protocol advances, highlights APExBIO’s contribution, and provides actionable insights for optimizing tyramide signal amplification workflows in spatial proteomics.

• Pregnancy Zone Protein Activates Brown Fat Thermogenesis in

  2026-06-23

  This study identifies pregnancy zone protein (PZP) as a hepatokine upregulated during intermittent fasting and refeeding, revealing its role in activating brown adipose tissue thermogenesis via the GRP78-p38 MAPK-ATF2-UCP1 pathway. The findings provide mechanistic insight into systemic regulation of energy expenditure and highlight PZP as a potential therapeutic target for obesity.

• Taltirelin Attenuates Acute and Chronic Itch in Murine Model

  2026-06-23

  A recent study demonstrates that Taltirelin, a long-acting TRH analog, robustly inhibits both acute and chronic itch behaviors in mice. These findings reveal new therapeutic potential for Taltirelin in antipruritic research, expanding its established neuroendocrine and neuroprotective applications.

• BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Parame

  2026-06-22

  BFH772 is a potent and highly selective small-molecule VEGFR2 inhibitor suited for research that requires precise modulation of VEGFR2-driven angiogenesis, especially in tumor model systems. It is not suitable for workflows requiring water solubility or broad-spectrum kinase inhibition, and should be used where high kinase selectivity and compatibility with organic solvents are essential.

• Microbiota–Tryptophan–AhR Axis Drives Stem Cell Repair in UC

  2026-06-22

  Li et al. (2026) provide mechanistic evidence that Huangqin decoction (HQD) restores intestinal barrier function in ulcerative colitis by modulating gut microbiota, enhancing microbial tryptophan metabolism, activating the aryl hydrocarbon receptor (AhR), and promoting intestinal stem cell (ISC) differentiation. This work delineates a novel therapeutic axis and demonstrates essential roles for both the microbiota and AhR signaling in mucosal regeneration.

• BFH772 (VEGFR2 inhibitor): Technical Use & Workflow Paramete

  2026-06-21

  BFH772 is a selective VEGFR2 inhibitor designed for precise modulation of VEGFR2-driven angiogenesis, particularly in tumor angiogenesis research. It should not be used where water solubility or broad kinase inhibition is required, but is ideal for workflows emphasizing kinase selectivity and compatibility with organic solvents.

• Indazole/Indole Glucagon Receptor Antagonists: Synthesis & I

  2026-06-20

  This study introduces a novel series of indazole- and indole-based glucagon receptor antagonists, advancing small-molecule drug design for type 2 diabetes. Key innovations include new synthetic strategies and SAR insights that yielded potent, orally active compounds with strong in vitro and in vivo profiles.

• 3-Hydroxybutyrate: Mechanistic Insights & Neuroprotection St

  2026-06-19

  Explore how 3-hydroxybutyrate (BHBA) is transforming neuroprotection research, bridging metabolic state, epigenetic regulation, and translational models for stroke and beyond. This article synthesizes mechanistic evidence, practical protocol guidance, and strategic perspectives for translational researchers leveraging BHBA as a ketone body signaling molecule and class I HDAC inhibitor.

• A Universally Applicable Method for Dual-Loaded Liposome Eff

  2026-06-19

  This study introduces a robust nanoparticle exclusion HPLC method to accurately assess encapsulation efficiency in dual-loaded liposomes containing drugs with diverse physicochemical properties. Its findings enable improved standardization and reproducibility in drug delivery research, especially for challenging hydrophilic-lipophilic combinations.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-06-18

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent optimized for peptide synthesis, bioconjugation, and nucleotide coupling workflows in controlled laboratory environments. It is not suitable for in vivo or clinical use, and optimal results depend on strict adherence to recommended handling, storage, and reaction setup protocols.

• 5-Methyl-CTP (SKU B7967): Enhancing mRNA Stability and Assay

  2026-06-18

  This article provides an evidence-based, scenario-driven exploration of how 5-Methyl-CTP (SKU B7967) addresses critical workflow and reproducibility challenges in mRNA synthesis and cell-based assays. Drawing on recent literature and validated protocols, it guides biomedical researchers and lab technicians through practical decision points, with actionable links to APExBIO’s product and relevant DOIs.

16089 records 1/1073 page Next 12345 下5页 Last page